ANCA-associated vasculitis (Q98778531)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32855422%20AND%20SRC:MED&resulttype=core&format=json

30 August 2020

title

ANCA-associated vasculitis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32855422%20AND%20SRC:MED&resulttype=core&format=json

30 August 2020

Paul A Lyons

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32855422%20AND%20SRC:MED&resulttype=core&format=json

30 August 2020

A Richard Kitching

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32855422%20AND%20SRC:MED&resulttype=core&format=json

30 August 2020

Hans-Joachim Anders

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32855422%20AND%20SRC:MED&resulttype=core&format=json

30 August 2020

Neil Basu

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32855422%20AND%20SRC:MED&resulttype=core&format=json

30 August 2020

Elisabeth Brouwer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32855422%20AND%20SRC:MED&resulttype=core&format=json

30 August 2020

Jennifer Gordon

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32855422%20AND%20SRC:MED&resulttype=core&format=json

30 August 2020

David R Jayne

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32855422%20AND%20SRC:MED&resulttype=core&format=json

30 August 2020

Joyce Kullman

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32855422%20AND%20SRC:MED&resulttype=core&format=json

30 August 2020

Peter A Merkel

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32855422%20AND%20SRC:MED&resulttype=core&format=json

30 August 2020

Caroline O S Savage

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32855422%20AND%20SRC:MED&resulttype=core&format=json

30 August 2020

Ulrich Specks

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32855422%20AND%20SRC:MED&resulttype=core&format=json

30 August 2020

Renate Kain

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32855422%20AND%20SRC:MED&resulttype=core&format=json

30 August 2020

publication date

27 August 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32855422%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Disease Primers

30 August 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32855422%20AND%20SRC:MED&resulttype=core&format=json

30 August 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32855422%20AND%20SRC:MED&resulttype=core&format=json

30 August 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32855422%20AND%20SRC:MED&resulttype=core&format=json

30 August 2020

page(s)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32855422%20AND%20SRC:MED&resulttype=core&format=json

Classification, epidemiology and clinical subgrouping of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.

30 August 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

The epidemiology of ANCA associated vasculitis in Olmsted County, Minnesota (USA): a 20 year population-based study.

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Prevalence of Wegener's granulomatosis, microscopic polyangiitis, polyarteritis nodosa and Churg-Strauss syndrome within a defined population in southern Sweden.

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Mortality in ANCA-associated vasculitis: ameta-analysis of observational studies

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

The characterisation and determinants of quality of life in ANCA associated vasculitis.

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Clinical and Economic Burden of Antineutrophil Cytoplasmic Antibody-associated Vasculitis in the United States.

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Evaluation of a new algorithm in classification of systemic vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Renal vasculitis in Japan and the UK--are there differences in epidemiology and clinical phenotype?

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Geoepidemiology of systemic vasculitis: comparison of the incidence in two regions of Europe

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Wegener's granulomatosis in New Zealand: evidence for a latitude-dependent incidence gradient.

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

DRB1*15 allele is a risk factor for PR3-ANCA disease in African Americans

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener's granulomatosis, and Churg-Strauss syndrome in a French urban multiethnic population in 2000: a capture-recapture estimate

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Incidence of ANCA-associated vasculitis in a UK mixed ethnicity population

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Childhood-onset granulomatosis with polyangiitis and microscopic polyangiitis: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Clinical course of anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and systemic vasculitis. The Glomerular Disease Collaborative Network

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Patients hospitalized because of small vessel vasculitides with renal involvement in the period 1975-95: organ involvement, anti-neutrophil cytoplasmic antibodies patterns, seasonal attack rates and fluctuation of annual frequencies

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

The contrasting epidemiology of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Seasonal variations in the onset of positive and negative renal ANCA-associated vasculitis in Spain

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

No seasonal variation in the onset of symptoms of 445 patients with Wegener's granulomatosis

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Are environmental factors important in primary systemic vasculitis? A case-control study

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Significantly high regional morbidity of MPO-ANCA-related angitis and/or nephritis with respiratory tract involvement after the 1995 great earthquake in Kobe (Japan).

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Incidence of anti-neutrophil cytoplasmic antibody-associated vasculitis before and after the February 2011 Christchurch Earthquake

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

The epidemiology of Wegener's granulomatosis. Estimates of the five-year period prevalence, annual mortality, and geographic disease distribution from population-based data sources

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

The frequency of ANCA-associated vasculitis in a national database of hospitalized patients in China

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Antineutrophil cytoplasmic antibody-associated vasculitides: could geographic patterns be explained by ambient ultraviolet radiation?

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Association of Cigarette Smoking With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

ANCA-Associated Vasculitis: Pathogenesis, Models, and Preclinical Testing.

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Risks and relative risks of Wegener's granulomatosis among close relatives of patients with the disease

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

New genomic region for Wegener's granulomatosis as revealed by an extended association screen with 202 apoptosis-related genes

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Genetically distinct subsets within ANCA-associated vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Association of granulomatosis with polyangiitis (Wegener's) with HLA-DPB1*04 and SEMA6A gene variants: evidence from genome-wide analysis

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Identification of Functional and Expression Polymorphisms Associated With Risk for Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

PTPN22 and autoimmune disease

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Genomic atlas of the human plasma proteome

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

A subset of HLA-DP molecules serve as ligands for the natural cytotoxicity receptor NKp44

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Enhanced formation and disordered regulation of NETs in myeloperoxidase-ANCA-associated microscopic polyangiitis

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

A plasmid-encoded peptide from Staphylococcus aureus induces anti-myeloperoxidase nephritogenic autoimmunity

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Gene-Specific DNA Methylation Changes Predict Remission in Patients with ANCA-Associated Vasculitis.

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Netting neutrophils in autoimmune small-vessel vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Proteinase 3: the odd one out that became an autoantigen

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Complement receptor Mac-1 is an adaptor for NB1 (CD177)-mediated PR3-ANCA neutrophil activation

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Neutrophil-Mediated Regulation of Innate and Adaptive Immunity: The Role of Myeloperoxidase

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Neutrophil myeloperoxidase harbors distinct site-specific peculiarities in its glycosylation

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Molecular mimicry in pauci-immune focal necrotizing glomerulonephritis

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Autoimmunity is triggered by cPR-3(105-201), a protein complementary to human autoantigen proteinase-3.

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

ANCA patients have T cells responsive to complementary PR-3 antigen

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

A novel autoantibody against moesin in the serum of patients with MPO-ANCA-associated vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Antibodies with dual reactivity to plasminogen and complementary PR3 in PR3-ANCA vasculitis.

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Anti-Plasminogen Antibodies Compromise Fibrinolysis and Associate with Renal Histology in ANCA-Associated Vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Anti-LAMP-2 antibodies are not prevalent in patients with antineutrophil cytoplasmic autoantibody glomerulonephritis

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Asymptomatic autoantibodies associate with future anti-glomerular basement membrane disease

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Natural autoantibodies to myeloperoxidase, proteinase 3, and the glomerular basement membrane are present in normal individuals

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Thymic deletion and regulatory T cells prevent antimyeloperoxidase GN.

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Functional defect of circulating regulatory CD4+ T cells in patients with Wegener's granulomatosis in remission

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Patients with antineutrophil cytoplasmic antibody-associated vasculitis have defective Treg cell function exacerbated by the presence of a suppression-resistant effector cell population.

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Decreased CD5⁺ B cells in active ANCA vasculitis and relapse after rituximab.

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Regulatory B cells in ANCA-associated vasculitis.

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Restricted myeloperoxidase epitopes drive the adaptive immune response in MPO-ANCA vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

The immunodominant myeloperoxidase T-cell epitope induces local cell-mediated injury in antimyeloperoxidase glomerulonephritis.

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Epitope specificity determines pathogenicity and detectability in ANCA-associated vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

CD8+ T Cells Effect Glomerular Injury in Experimental Anti-Myeloperoxidase GN.

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Anti-myeloperoxidase autoantibodies react with native but not denatured myeloperoxidase

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Anti-native and recombinant myeloperoxidase monoclonals and human autoantibodies

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Serum Levels of BAFF and APRIL in Myeloperoxidase Anti-Neutrophil Cytoplasmic Autoantibody-Associated Renal Vasculitis: Association with Disease Activity

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

ANCA-stimulated neutrophils release BLyS and promote B cell survival: a clinically relevant cellular process

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Effector and regulatory B cells in immune-mediated kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Analysis and classification of B-cell infiltrates in lupus and ANCA-associated nephritis

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

IgA and IgG antineutrophil cytoplasmic antibody engagement of Fc receptor genetic variants influences granulomatosis with polyangiitis

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Activation of the G(i) heterotrimeric G protein by ANCA IgG F(ab')2 fragments is necessary but not sufficient to stimulate the recruitment of those downstream mediators used by intact ANCA IgG.

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Activation of Syk in neutrophils by antineutrophil cytoplasm antibodies occurs via Fcgamma receptors and CD18.

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Up-regulation of the granulocyte adhesion molecule Mac-1 by autoantibodies in autoimmune vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Antimyeloperoxidase antibodies rapidly induce alpha-4-integrin-dependent glomerular neutrophil adhesion.

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

ANCA-induced neutrophil F-actin polymerization: implications for microvascular inflammation

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

ANCA Glomerulonephritis and Vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Anti-neutrophil cytoplasmic antibodies stimulate release of neutrophil microparticles

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Neonatal microscopic polyangiitis secondary to transfer of maternal myeloperoxidase-antineutrophil cytoplasmic antibody resulting in neonatal pulmonary hemorrhage and renal involvement

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

The role of neutrophils in the induction of glomerulonephritis by anti-myeloperoxidase antibodies

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Antineutrophil cytoplasmic autoantibodies against the murine homolog of proteinase 3 (Wegener autoantigen) are pathogenic in vivo

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Reactivity of antineutrophil cytoplasmic autoantibodies with mononuclear phagocytes

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Autoantibodies to hLAMP-2 in ANCA-negative pauci-immune focal necrotizing GN

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Sialylation levels of anti-proteinase 3 antibodies are associated with the activity of granulomatosis with polyangiitis (Wegener's)

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Immunoglobulins G from patients with ANCA-associated vasculitis are atypically glycosylated in both the Fc and Fab regions and the relation to disease activity

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Epigenetic basis for aberrant upregulation of autoantigen genes in humans with ANCA vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Neutrophils from vasculitis patients exhibit an increased propensity for activation by anti-neutrophil cytoplasmic antibodies.

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Neutrophils from ANCA-associated vasculitis patients show an increased capacity to activate the complement system via the alternative pathway after ANCA stimulation.

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Intrinsic renal cell and leukocyte-derived TLR4 aggravate experimental anti-MPO glomerulonephritis.

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Bacterial DNA motifs trigger ANCA production in ANCA-associated vasculitis in remission

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Toll-like receptor TLR2 and TLR9 ligation triggers neutrophil activation in granulomatosis with polyangiitis

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

High mobility group box 1 contributes to anti-neutrophil cytoplasmic antibody-induced neutrophils activation through receptor for advanced glycation end products (RAGE) and Toll-like receptor 4.

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

C5a receptor (CD88) blockade protects against MPO-ANCA GN

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Biomarkers: to be or not to be

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Inhibition of complement factor C5 protects against anti-myeloperoxidase antibody-mediated glomerulonephritis in mice

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

C5a receptor 1 promotes autoimmunity, neutrophil dysfunction and injury in experimental anti-myeloperoxidase glomerulonephritis

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Experimentally-induced anti-myeloperoxidase vasculitis does not require properdin, MASP-2 or bone marrow-derived C5

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Alternative complement pathway activation products in urine and kidneys of patients with ANCA-associated GN

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Complement in ANCA-associated vasculitis: mechanisms and implications for management

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Association of Serum C3 Concentration and Histologic Signs of Thrombotic Microangiopathy with Outcomes among Patients with ANCA-Associated Renal Vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

ANCA induces beta2 integrin and CXC chemokine-dependent neutrophil-endothelial cell interactions that mimic those of highly cytokine-activated endothelium

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Antineutrophil cytoplasm antibodies directed against myeloperoxidase augment leukocyte-microvascular interactions in vivo

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Mechanisms of ANCA-mediated leukocyte-endothelial cell interactions in vivo.

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Predominance of IgGl and IgG4 subclasses of anti-neutrophil cytoplasmic autoantibodies (ANCA) in patients with Wegener's granulomatosis and clinically related disorders

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Increased frequency of circulating IL-21 producing Th-cells in patients with granulomatosis with polyangiitis (GPA).

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Urinary CD4+ effector memory T cells reflect renal disease activity in antineutrophil cytoplasmic antibody-associated vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Pulmonary vasculitis (Wegener's granulomatosis). Immunohistochemical study of T and B cell markers

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Histologic analysis of renal leukocyte infiltration in antineutrophil cytoplasmic antibody-associated vasculitis: importance of monocyte and neutrophil infiltration in tissue damage

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Renal participation of myeloperoxidase in antineutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis.

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Serum IL-17 and IL-23 levels and autoantigen-specific Th17 cells are elevated in patients with ANCA-associated vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Cytokine profiles in Wegener's granulomatosis: predominance of type 1 (Th1) in the granulomatous inflammation.

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

The host cellular immune response to cytomegalovirus targets the endothelium and is associated with increased arterial stiffness in ANCA-associated vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Subclinical Reactivation of Cytomegalovirus Drives CD4+CD28null T-Cell Expansion and Impaired Immune Response to Pneumococcal Vaccination in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

A CD8+ T cell transcription signature predicts prognosis in autoimmune disease

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection.

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Colocalization of ANCA-antigens and fibrinoid necrosis in ANCA-associated vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Biologicals targeting T helper cell subset differentiating cytokines are effective in the treatment of murine anti-myeloperoxidase glomerulonephritis

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Monocytes Promote Crescent Formation in Anti-Myeloperoxidase Antibody-Induced Glomerulonephritis

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Interleukin-25: a cytokine linking eosinophils and adaptive immunity in Churg-Strauss syndrome.

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Elevated interleukin-4 and interleukin-13 production by T cell lines from patients with Churg-Strauss syndrome

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Increased production of IL-5 and dominant Th2-type response in airways of Churg–Strauss syndrome patients

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

A blood-based prognostic biomarker in IBD

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Introduction, epidemiology and classification of vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Nomenclature and classification of vasculitis – update on the ACR/EULAR Diagnosis and Classification of Vasculitis Study (DCVAS)

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Systemic vasculitis presenting as a tumorlike lesion. Four case reports and an analysis of 79 reported cases

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Small-Vessel Vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Antineutrophil Cytoplasmic Antibody-Associated Lung Fibrosis

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Comparison of phenotype and outcome in microscopic polyangiitis between Europe and Japan

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival, frequency of relapse, and outcomes compared to single-seropositive patients.

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Positive antineutrophil cytoplasmic antibody serology in patients with lupus nephritis is associated with distinct histopathologic features on renal biopsy.

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

MPO-ANCA-Positive crescentic glomerulonephritis: a distinct entity of scleroderma renal disease?

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Systemic vasculitis during the course of systemic sclerosis: report of 12 cases and review of the literature

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Childhood- versus adult-onset ANCA-associated vasculitides: A nested, matched case-control study from the French Vasculitis Study Group Registry

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Brief Report: Circulating Cytokine Profiles and Antineutrophil Cytoplasmic Antibody Specificity in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

ANCA-associated vasculitis - clinical utility of using ANCA specificity to classify patients

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Position paper: Revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis.

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Reconstitution of the peripheral B lymphocyte compartment in patients with ANCA-associated vasculitides treated with rituximab for relapsing or refractory disease

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

CD27+CD38hi B Cell Frequency During Remission Predicts Relapsing Disease in Granulomatosis With Polyangiitis Patients

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Urinary Soluble CD163 in Active Renal Vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Update on ANCA-associated vasculitis: from biomarkers to therapy

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Urinary and serum soluble CD25 complements urinary soluble CD163 to detect active renal anti-neutrophil cytoplasmic autoantibody-associated vasculitis: a cohort study

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Clinical features and structured clinical evaluation of vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Modification and validation of the Birmingham Vasculitis Activity Score (version 3)

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort.

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Development and initial validation of the vasculitis damage index for the standardized clinical assessment of damage in the systemic vasculitides

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

The OMERACT core set of outcome measures for use in clinical trials of ANCA-associated vasculitis.

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Increased incidence of cardiovascular events in patients with antineutrophil cytoplasmic antibody-associated vasculitides: a matched-pair cohort study

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Damage in the anca-associated vasculitides: long-term data from the European vasculitis study group (EUVAS) therapeutic trials.

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Thrombosis in vasculitis: from pathogenesis to treatment

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener's Clinical Occurrence of Thrombosis (WeCLOT) Study

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Clinical and laboratory characteristics of 19 patients with Churg-Strauss syndrome from a single South Australian centre.

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Pulmonary Involvement in Antineutrophil Cytoplasmic Antibodies (ANCA)-associated Vasculitis: The Influence of ANCA Subtype.

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Subglottic stenosis and endobronchial disease in granulomatosis with polyangiitis

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Histopathologic classification of ANCA-associated glomerulonephritis

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Histopathological classification of antineutrophil cytoplasmic antibody-associated glomerulonephritis: an update

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Development and validation of a renal risk score in ANCA-associated glomerulonephritis

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Neurological Involvement in Primary Systemic Vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Long-term patient survival in ANCA-associated vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Trends in Long-Term Outcomes Among Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis With Renal Disease

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Trends in Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis-Related Mortality in the United States, 1999 to 2017

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Worldwide trends in all-cause mortality of auto-immune systemic diseases between 2001 and 2014

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Effect of Disease Activity at Three and Six Months After Diagnosis on Long-Term Outcomes in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial.

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up.

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Rituximab versus cyclophosphamide for ANCA-associated vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Efficacy of remission-induction regimens for ANCA-associated vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Long-Term Rituximab Use to Maintain Remission of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Trial

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Rituximab versus azathioprine as therapy for maintenance of remission for anti-neutrophil cytoplasm antibody-associated vasculitis (RITAZAREM): study protocol for a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Rituximab for maintenance of remission in ANCA-associated vasculitis: expert consensus guidelines

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Adding Azathioprine to Remission-Induction Glucocorticoids for Eosinophilic Granulomatosis with Polyangiitis, Microscopic Polyangiitis or Polyarteritis Nodosa without Poor Prognosis Factors A Randomized-Controlled Trial

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Efficacy and safety of rituximab in the treatment of eosinophilic granulomatosis with polyangiitis.

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Immunoglobulin G replacement for the treatment of infective complications of rituximab-associated hypogammaglobulinemia in autoimmune disease: a case series

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Venous thromboembolism with concurrent pulmonary haemorrhage in systemic vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Incidence of malignancy in patients treated for antineutrophil cytoplasm antibody-associated vasculitis: follow-up data from European Vasculitis Study Group clinical trials

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Effect of rituximab on malignancy risk in patients with ANCA-associated vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Glucocorticoid-Induced Osteoporosis

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Long-term outcome of airway stenosis in granulomatosis with polyangiitis (Wegener granulomatosis): an observational study

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Characteristics and Outcomes of Granulomatosis With Polyangiitis (Wegener) and Microscopic Polyangiitis Requiring Renal Replacement Therapy: Results From the European Renal Association-European Dialysis and Transplant Association Registry

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Patient-reported outcome assessment in vasculitis may provide important data and a unique perspective

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Patient perceptions of glucocorticoids in anti-neutrophil cytoplasmic antibody-associated vasculitis.

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

OMERACT Endorsement of Patient-reported Outcome Instruments in Antineutrophil Cytoplasmic Antibody-associated Vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

The Longitudinal Course of Fatigue in Antineutrophil Cytoplasmic Antibody-associated Vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Leg muscle strength is reduced and is associated with physical quality of life in Antineutrophil cytoplasmic antibody-associated vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Treatment of systemic necrotizing vasculitides in patients aged sixty-five years or older: results of a multicenter, open-label, randomized controlled trial of corticosteroid and cyclophosphamide-based induction therapy

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Long-term follow-up of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Evaluation of the Safety and Efficacy of Avacopan, a C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Treated Concomitantly With Rituximab or Cyclophosphamide/Azathioprine: Protocol for a Randomized,

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Brief Report: long-term outcome of a randomized clinical trial comparing methotrexate to cyclophosphamide for remission induction in early systemic antineutrophil cytoplasmic antibody-associated vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Azathioprine or methotrexate maintenance for ANCA-associated vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Long-Term Outcomes Among Participants in the WEGENT Trial of Remission-Maintenance Therapy for Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Etanercept plus standard therapy for Wegener's granulomatosis

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Treatment of Churg-Strauss syndrome without poor-prognosis factors: A multicenter, prospective, randomized, open-label study of seventy-two patients

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Non-severe eosinophilic granulomatosis with polyangiitis: long-term outcomes after remission-induction trial

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Lack of superiority of steroids plus plasma exchange to steroids alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome. A prospective, randomized trial in 78 patients

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Corticosteroids plus pulse cyclophosphamide and plasma exchanges versus corticosteroids plus pulse cyclophosphamide alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome patients with factors predicting poor prognosis. A prospect

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

An open-label trial of abatacept (CTLA4-IG) in non-severe relapsing granulomatosis with polyangiitis (Wegener's).

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Biologics for the treatment of autoimmune renal diseases.

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Apoptotic Cell-Induced, Antigen-Specific Immunoregulation to Treat Experimental Antimyeloperoxidase GN

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Gleaning relapse risk from B cell phenotype: decreased CD5+ B cells portend a shorter time to relapse after B cell depletion in patients with ANCA-associated vasculitis.

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Epidemiology of primary systemic vasculitis in the Australian Capital Territory and south-eastern New South Wales

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Does geographic location affect incidence of ANCA-associated renal vasculitis in northern Saskatchewan, Canada?

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Stable incidence of primary systemic vasculitides over five years: results from the German vasculitis register

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Comparison of the epidemiology of anti-neutrophil cytoplasmic antibody-associated vasculitis between Japan and the U.K.

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Incidence of primary systemic vasculitides in Vilnius: a university hospital population based study

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

The epidemiology of the primary systemic vasculitides in northwest Spain: implications of the Chapel Hill Consensus Conference definitions

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Incidence and survival rates in Wegener's granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and polyarteritis nodosa.

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

The Incidence of Primary Systemic Vasculitis in Jerusalem: A 20-year Hospital-based Retrospective Study.

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

An international survey on anti-neutrophil cytoplasmic antibodies (ANCA) testing in daily clinical practice

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Detection of antineutrophil cytoplasmic antibodies (ANCAs): a multicentre European Vasculitis Study Group (EUVAS) evaluation of the value of indirect immunofluorescence (IIF) versus antigen-specific immunoassays

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

International Consensus Statement on Testing and Reporting of Antineutrophil Cytoplasmic Antibodies (ANCA)

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

The clinical presentation and therapy of diseases related to anti-neutrophil cytoplasmic antibodies (ANCA).

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Autoantibodies against bactericidal/permeability-increasing protein in patients with cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Subacute bacterial endocarditis with positive cytoplasmic antineutrophil cytoplasmic antibodies and anti-proteinase 3 antibodies

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Brief report: prevalence of antineutrophil cytoplasmic antibodies in infective endocarditis.

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Propylthiouracil-induced antineutrophil cytoplasmic antibody-associated vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Trojan horses: drug culprits associated with antineutrophil cytoplasmic autoantibody (ANCA) vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Drug-Induced Vasculitis: New Insights and a Changing Lineup of Suspects

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Inactivation of peroxidases of rat bone marrow by repeated administration of propylthiouracil is accompanied by a change in the heme structure

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Abnormal conformation and impaired degradation of propylthiouracil-induced neutrophil extracellular traps: implications of disordered neutrophil extracellular traps in a rat model of myeloperoxidase antineutrophil cytoplasmic antibody-associated vas

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

Comment on: Decreased platelet size is associated with platelet activation and anti-phospholipid syndrome in systemic lupus erythematosus: reply

1 reference

https://api.crossref.org/works/10.1038%2FS41572-020-0204-Y

7 January 2021

10.1038/S41572-020-0204-Y

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32855422%20AND%20SRC:MED&resulttype=core&format=json

30 August 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32855422%20AND%20SRC:MED&resulttype=core&format=json